Recent studies show that regulatory T cells (Tregs) play an essential role in tolerance induction after organ transplantation. In order to examine whether there are differences in the composition of the total CD4 + CD127 low+/2 FoxP3 +
Introduction
Despite the significant improvement in the understanding of allo-immune mechanisms for graft failure and the development of innovative immune-suppressants, graft and patient survival have not increased as expected in the past decade. Prevention of graft rejection and induction of tolerance are common goals in the field of transplantation. Acute rejection has been shown to be one of the strongest negative prognostic factors for long-term graft survival after kidney transplantation [1, 2] . The frequency of acute rejection episodes is highest during the first 6 months after transplantation [3] . During the second and third year post surgery, renal function becomes stable and the incidence of acute rejection and graft loss is markedly reduced [4] . After more than three years, only small changes can be observed in regard to mean GFR decline, annual incidence of graft loss and death, which all were found to represent about 1%. Currently, only limited data exist which could explain this phenomenon. Possibly, several transplant patients can develop tolerance towards the foreign allo-antigens with advancing time after transplantation.
Recent studies show that regulatory T cells (Tregs) play an essential role in tolerance induction after organ transplantation [5, 6] . The majority of such studies were done using animal models. However, in humans, the true function of Tregs in alloimmunity remains in question [7, 8] . Currently, Treg cells are broadly subdivided into those that develop in the thymus (natural (n) Tregs) and those that develop from conventional T-cells in the periphery (induced (i) Tregs) [9] . A specific cell marker that differentiates human nTregs from iTregs is not yet known. Both Treg populations potentially suppress the proliferation of T effector-cells [9] and are characterized by simultaneous expression of the interleukin (IL) 2 receptor a chain (CD25) and the forkhead box P3 (FoxP3) transcription factor [10] . In addition, an inverse correlation between the expression of the IL-7 receptor a chain (CD127) and their suppressive function was observed for CD4 + CD25 + FoxP3 + -Treg cells [11, 12] . Currently, it is not known, to which extent each of these Treg populations contributes to the prevention of allograft rejection after transplantation. However, there is a growing body of evidence that the suppressive potency of the total Treg cell pool may depend on its composition with distinct Treg subsets. Baecher-Allan et al. have characterized a highly suppressive subset of Treg cells expressing HLA-class II (DR) antigens [13] . Such HLA-DR + -Tregs were shown to express higher levels of FoxP3 and induced a more intense and a more rapid T cell suppression than the Tregs that lack HLA-DR expression [13] . Moreover, it is known that the total Treg pool contains a population of naïve CD45RA
+ -Treg cells. Its proportion decreases with increasing age and it was shown that naïve CD45RA + -Treg cells were less proliferative than their CD45RO + counterparts [14] . Recent data demonstrate that the suppressive activity of naïve CD45RA
+ -Treg cells is impaired in multiple sclerosis (MS) patients, suggesting that this Treg population may potentially be involved in the pathology of autoimmune diseases [15, 16] .
In the present study, we demonstrate that DR high+ CD45RA 2 -Tregs potentially affect the suppressive activity of the total Treg pool and that the disappearance of this Treg subset gives a strong indication for acute rejection processes.
Results
The percentage of CD4 Figure 1 ). PBMCs obtained from each participant were stained with anti-CD4, anti-CD127, anti-FoxP3, anti-HLA-DR and anti-CD45RA monoclonal antibodies and analyzed by five color flow cytometric analysis. 
CD45RA
2 -Treg subset (Fig. 2C, P3 ) and the percentages of DR low+ CD45RA 2 -Tregs (Fig. 2D, P6 ) and DR high+ CD45RA 2 -Tregs (Fig. 2D, P7 ) of the total Treg cell pool (P2) were documented. Figure 3 + -Tregs at different time points (G1-G3) after transplantation between rejecting and non-rejecting patients were not detected.
The suppressive activity of the CD4 + CD127 low+/2 CD25 + -Treg cell pool is significantly reduced in patients with biopsy proven rejection (BPR)
To examine whether there were differences in the suppressive activity of the total Treg pool between rejecting and non-rejecting transplant patients we used coculture suppression assays described in the methods section. To evaluate the suppressive capacity of CD4 + CD127 low+/2 CD25 + -Tregs, obtained from the different patient groups (Group A-C), we determined the maximum suppressive activity (ratio of Treg cells to responder T (Tresp) cells 1:1) and calculated the ratio of Treg cells to Tresp cells that resulted in a suppression of at least 15%. Figure 4A depicts the results of one representative experiment obtained for healthy nontransplanted volunteers (Group A), stable kidney transplant patients (Group B) and transplant patients with BPR (Group C), respectively. Figure 4B and 4C summarize the data for the individual participants in each of these three patient groups. We found that the suppressive activity of the isolated CD4 + CD127 low+/2 CD25 + -Tregs, obtained from stable transplant recipients, was in the same range as that of CD4 + CD127
low+/2 CD25 + -Tregs obtained from healthy non-transplanted volunteers. In contrast, the suppressive activity of Tregs obtained from patients with acute rejection was significantly reduced compared to healthy non-transplanted controls and to stable transplant patients, ( Figure 4B ). Furthermore, the ratio of Treg cells to responder cells (Titer Treg/Tresp) leading to a suppression of at least 15%, was significantly decreased in patients with acute rejection compared to healthy controls and stable transplant patients ( Figure 4C ).
After transplantation, the composition of the total Treg cell pool changes characteristically Figures 5A-4D summarize the results of these analyses. The individual ratios of the four Treg subsets showed characteristic changes over time in transplanted patients. Therefore, the transplant patients were grouped depending on the period of time after surgery (G1: 0-30 days, G2: 31-1000 days, G3: .1000 days). Non-transplanted volunteers served as healthy controls (Group A). Compared to healthy non-transplanted controls (Group A), the percentage of DR high+ CD45RA 2 -Tregs decreased strongly within the first 30 days after transplantation (Fig. 5A, G1 ) and remained at minimum levels up to 1000 days post surgery (Fig. 5A, (G2) ). The percentage of DR low+ CD45RA 2 -Tregs increased initially (Fig. 5B, G1 ), but decreased subsequently and reached the lowest levels between 31 and 1000 days post transplantation (Fig. 5B, (G2) ). After a period of 1000 days (G3) both the percentages of DR high+ CD45RA
2 -Tregs and DR low+ C-D45RA 2 -Tregs returned to levels in the range of healthy nontransplanted controls (Group A), (Figures 5A and 5B ). As the differentiation between DR high+ CD45RA 2 -Tregs and DR low+ C-D45RA
2 -Tregs was difficult, we additionally estimated the HLA-DR mean fluorescence intensity (MFI) of the DR + CD45RA 2 -Treg cell subset for all participants (Fig. 5E ). We found a dramatic decrease within the first days after surgery (Fig. 5E, G1) , it is likely due to a strong decrease of the DR high+ CD45RA 2 -Treg subset and an increase of the DR low+ CD45RA 2 -Treg subset. However, subsequently a continuous increase of the HLA-DR MFI could be documented (Fig. 5E , G2-G3), because in the period between 30-1000 days post surgery (Fig. 4E, G2 The percentage of the naïve DR 2 CD45RA + -Treg subset decreased significantly during the first 30 days after transplantation (Fig. 5C, G1 ), but afterwards, it increased strongly and reached maximum levels between 31 and 1000 days post surgery (Fig. 5C, G2 ). After 1000 days post surgery, a significant decrease of this Treg subset was observed (Fig. 5C, G3 ).
The percentage of the DR 2 CD45RA 2 -Treg subset increased immediately after transplantation (Fig. 5D, G1 ) and revealed the highest levels between 31 and 1000 days after surgery (Fig. 5D , G2). After more than 1000 days post transplantation (Fig. 5D, G3 ), a slight but significant decrease was observed. 
2 -Treg cell subset. All parameters were determined during the three different periods of time after transplantation (G1: 0-30 days, G2: 31-1000 days, G3: .1000 days). Figure 5A -5E and Table 2 show the results of these measurements.
Among 156 transplant patients, 37 patients suffered from BPR. The most prominent differences between non-rejecting (Group B) and rejecting BPR patients (Group C) were seen regarding the DR high+ CD45RA 2 -Treg cell subset. BPR patients showed a 32% reduction of this Treg subset within the total Treg cell pool after 31-1000 days (G2) and a 44% reduction after more than 1000 days post surgery (G3) versus patients without rejection. Differences concerning the DR low+ CD45RA 2 -Treg subset could not be detected. In parallel, the HLA-DR MFI of the DR + CD45RA 2 -Treg cell subset was strongly reduced in patients with BPR versus no BPR (31% after 31-1000 days (G2); 38% after 1000 days (G3)). Figure 4E shows the relationship of the HLA-DR MFI of the DR +
2 -Treg cell subset and the time after transplantation for stable transplant patients (Group B) and for patients with BPR (Group C). A positive linear correlation was found for stable transplant patients (r = 0.569, p,0.00001) and for patients with BPR (r = 0.664, p,0.00001). Comparison of these two regression lines revealed significant differences (p,0.001) between rejecting and non-rejecting transplant patients.
Moreover, contrary to stable transplant patients, BPR patients revealed a significantly higher proportion of DR 2 CD45RA 2 -Tregs after 30 days post surgery. Their percentage within the total Treg cell pool was 21% higher after 31 days (G2) and 39% higher after 1000 days post transplantation (G3). The percentage of the naïve DR 2 CD45RA + -Treg subset was lower in patients with BPR after 30 days post surgery, compared to patients with stable transplant function (G2 and G3). With regard to all examined parameters, there were no differences between rejecting and nonrejecting transplant patients during the first 30 days after surgery (G1). The low suppressive capacity of CD4 + CD127 low+/2 CD25 + -Tregs observed in BPR patients correlates with a decline of the HLA-DR MFI of the DR + CD45RA 2 -Treg subset
We examined whether there was a correlation between the HLA-DR MFI of the DR +
2 -Treg subset and the suppressive activity of the total Treg cell pool. Figure 6 shows the positive correlation (r = 0.546, p,0.001) between the HLA-DR MFI of the DR + CD45RA 2 -Treg subset and the titer (Treg/ Tresp) of Tregs, with which a minimum suppressive activity of 15% was achieved. Thereby, CD4 Figure 7A ). Subsequently, the suppressive activity of these different Treg subsets was analyzed. Both the maximum suppressive activity ( Figure 7B ) and the titer (Treg/ Tresp) with which a minimum suppressive activity of 15% could be achieved ( Figure 7C) 
Discussion
Therefore, Tregs play an important role in transplantation [5, 17] and pregnancy [18, 19] , but also influence infectious diseases [20] , autoimmunity [21] , and anti-tumor immunity [22] . Meanwhile, promising data in regard to solid organ transplantation are increasingly available. Considering the potential role of Tregs in 
FoxP3
+ Tregs of heart transplant patients who experienced acute rejection had a reduced regulatory function compared to those obtained from non-rejecting patients [26] . These and our results are contrary to the findings of a smaller study performed by Kreijveld et al. who did not find any differences concerning the suppressive activity between renal transplant recipients with rejection and those without rejection [27] .
Moreover, recent data revealed that the total Treg pool seems to be inconsistent. Different Treg subsets such as naïve CD45RA + -or HLA-DR + -expressing Treg cells were shown to be important for the functional activity of the total Treg cell pool [13, 15] . We demonstrated that differential expression of HLA-DR and CD45RA distinguished four different Treg subsets, which showed characteristic changes concerning their percentages within the total Treg pool during the time after transplantation. Initially after transplantation, the proportion of the naïve DR 
CD127
low+/2 CD25 + -Treg cells were isolated by the MACS technique and their suppressive activity was examined using suppression assays (see methods). One representative experiment is shown for healthy volunteers, kidney recipients with stable transplant function and kidney recipients with acute rejection. The maximum suppressive activity (Treg/Tresp = 1/1) (B) and the ratio of Treg/Tresp (titer) up to which the purified Treg cells could be diluted to achieve a minimum suppressive activity of at least 15% (C), were estimated for all participants. The figures show the individual and median data obtained for all patients groups. doi:10.1371/journal.pone.0034208.g004 + -Treg cells may be increasingly released by the thymus during the first year after transplantation. Presumably, after that time, the thymic output of Treg cells is exhausted. As HLA-DR + -Treg cells are known to represent highly activated mature Treg cells [13] , it seems likely that during the first year after transplantation such cells were preferentially eliminated, presumably due to permanent allogenic stimulation of the immune system. After that time, the maturation of the HLA-DR + -Treg cells outnumbers their elimination and the percentage of the HLA-DR + -Treg cells again increases to the level of healthy nontransplanted volunteers. In either case it seems that the changes in the percentages of the DR high+ -and DR low+ CD45RA 2 -Treg cells occur in the way that the HLA-DR MFI increases continuously after transplantation. Such findings may explain why transplant outcome studies have shown markedly reduced rejection rates after three years post surgery [3, 4] .
To determine whether there were differences in the composition of the total Treg cell pool between transplant patients with and without BPR, we determined the proportion of the different Treg cell subsets for both patient collectives. 
CD45RA
2 -Treg cell subset was observed in patients with BPR.
During pregnancy the ''fetal semi-allograft'' is perfectly tolerated by the maternal immune system. In a recent published study we demonstrated that women with preterm labor necessitating preterm delivery showed significantly reduced HLA-DR expression of CD4 +
CD127
low+/2 CD25 + FoxP3 + -Tregs, indicating that the immunologic mechanisms leading to preterm labor may be similar to those leading to allograft rejection after transplantation [28] . The underrepresentation of HLA-DR + -Treg cells in the neonatal compared with the adult circulation indicates that the presumed nTreg population gains HLA-DR expression upon + -Tregs are terminally differentiated effector Tregs, as they do not proliferate and are highly sensitive to apoptosis [30] . It was shown that Granzyme B, which was produced by strongly stimulated non-regulatory responder CD4 + -T cells, reduced especially the suppressive capacity of the non-proliferating HLA-DR + -Tregs cells [30] . On the other hand, the proliferation-competent HLA-DR 2 -Treg cells remained viable [30] and were shown to be more sensitive to Fas-L induced apoptosis [31] . Therefore, it may be hypothesized that the decrease in the MFI of the DR + CD45RA 2 -Treg cell subset obtained from rejecting kidney recipients may be caused by the increased Granzyme B induced apoptosis of DR +
CD45RA
2 -Treg cells which express the HLA-DR molecules very strongly. As it was ascertained that the Granzyme B induced apoptosis of the highly suppressive HLA-DR + -Treg cells happened preferentially in the case of strong responder T-cell stimulation [30] , it may be assumed that acute rejection episodes after transplantation that are characterized by strong stimulation of CD4 + -T cells lead to a loss of the strongly suppressive DR high+ -Treg-subset.
In summary, we clearly demonstrated that patients with biopsy proven rejection (BPR) show deficiencies concerning the functional activity of their Treg pool. Thereby, its composition was changed in the way that the DR high+ CD45RA 2 -Treg subset, which was shown to possess the highest suppressive activity, was decreased. In contrast, the DR 2 CD45RA 2 -Treg subset with lower suppressive capacity was increased in transplanted patients with acute rejection. Especially the determination of the HLA-DR MFI of the DR + CD45RA 2 -Treg subset allowed a significant discrimination between patients with acute graft rejection and those without rejection. The clinical usefulness of the monitoring of these peripheral blood parameters after solid organ transplantation and its relation to clinical outcomes needs to be investigated in large prospective cohort studies of transplant patients.
Materials and Methods

Study population
The study was approved by the Ethics Committee of the Medical Faculty Heidelberg. All patients and healthy controls were fully informed of the aim of the study and written informed consent was obtained from all participants. The study included 20 non-transplanted healthy volunteers (Group A) and 156 kidney transplant patients (Groups B and C) ( Table 1) . Forty-seven patients received a graft obtained from a living donor and 109 patients received a graft from a cadaveric donor. The mean age of our transplant cohort was 45 years (20-73 years) . The causes of end-stage renal failure in our transplant cohort were diabetes mellitus (38%, n = 59), vascular nephopathy (26%, n = 41), glomerulonephritis (15%, n = 23), autosomal dominant polycystic kidney disease (8%, n = 12), autoimmune diseases (5%, n = 8) like systemic lupus erythematosus and systemic vasculitis and 8% (n = 13) were unknown. Blood samples were obtained on the same day when kidney transplant recipients admitted to the Department of Nephrology for kidney biopsy. Kidney biopsies were classified according to the BANFFclassification [32, 33] . Biopsy proven rejection was defined as rising creatinine over 30% above the last three measurements and further pathological findings according to the BANFF-classification (Table 1) . Patients with acute graft failure because of infection, postrenal obstruction or drug induced renal failure were excluded. All transplant patients were further subdivided into three different groups. The first group (G1) contains transplant recipients before the 30th day after transplantation. The second group (G2) contains recipients between the 31st and the 1000th day after transplantation and the third group (G3) contains recipients more than 1000 days post transplantation. The 156 transplant patients received an immunosuppressive regime with Mycophenolic acid (MPA), Methylprednisolone and Calcineurininhibitors (Ciclosporin: 104 patients; Tacrolimus: 35 patients) or mTOR-Inhibitors (Everolimus: 13 patients, whereas 7 recipients received a combination of Cyclosporine and Everolimus) and 4 recipients received other immunosuppressive drugs (Table 1) .
Fluorescence-activated cell sorter (FACS) staining
Venous blood samples (9 ml) from all patients were collected into EDTA-containing tubes. Whole peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque (Amersham Bioscience) gradient centrifugation and analyzed by five color flow cytometric analysis. Briefly, PBMCs (4610 6 cells) were surfacestained with 10 ml PerCP-conjugated-anti-CD4 (BD Bioscience), 10 ml PE-conjugated anti-CD127 (eBioscience), 5 ml PE-Cy7-conjugated anti-HLA-DR (BD Bioscience) and 20 ml APCconjugated anti-CD45RA (BD Bioscience) mouse monoclonal antibodies. Intracellular staining for the detection of FoxP3 was achieved using a FITC labeled anti-human FoxP3 staining set (clone PCH101, eBioscience) according to the manufacturer's instructions. Both 
CD25
+ -Treg cells at ratios 1:1 to 1:256 in 96-well v-bottom plates. Suppression assays were performed in a final volume of 100 ml/ well of X-VIVO15 medium (Bio Whittaker). For T-cell stimulation, the medium was supplemented with 1 mg/ml anti-CD3 and 2 mg/ml anti-CD28 antibodies (eBioscience). As controls, CD4 + CD127 low+/2 CD25 + -Treg cells and responder T cells alone were cultured both with and without any stimulus. Cells were incubated at 37uC and 5% of CO 2 . After four days, 1 mCi 3 Hthymidine was added to the cultures and cells were further incubated for 16 hours. Then, cells were harvested and 3 H incorporation was measured by scintillation counting. All assays exhibited ,10% SEM and were performed a minimum of six times using blood from 6 different healthy non-transplanted volunteers, 32 healthy non-rejecting transplant patients and 17 transplant patients with acute rejection. In order to compare the suppressive capacity of the isolated CD4 + CD127 low+/2 CD25 + -Tregs between the different patient groups, we calculated the maximum suppressive activity (ratio of Treg cells to responder T cells 1:1) and the minimum ratio of Treg cells to responder cells, with which a suppression of at least 15% could be achieved.
Sorting and functional testing of the four different Treg cell subsets
Venous blood samples (100 ml) from six different healthy, nontransplanted volunteers were collected into EDTA-containing tubes. + -Treg cells. Subsequently, the suppressive activity of each Treg population was analyzed using the above described suppression assay. + -Tregs cells was also done using the Kruskal-Wallis-Test. P,0.05 was considered significant. Statistical analyses and graphs were performed using GraphPad Prism version 5 (San Diego, CA, USA) and BiAS 9.14 for windows (Frankfurt, Germany).
Statistical analysis
